Breaking the bottleneck: why Oklo’s bet on Atomic Alchemy could change cancer care
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.